Silo Pharma, Inc. Cash Flow Statement
SILO|5 years of annual SEC 10-K data (FY2019-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 5 fiscal years. All figures from audited SEC 10-K filings.
Silo Pharma, Inc. used $4M in operating cash flow in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 0.67 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Net Income | -$4.4M | -$3.7M | -$3.9M | -$1.0M | -$969.5K |
| Operating Cash Flow | -$3.8M | -$3.2M | -$3.5M | -$794.3K | $272.6K |
| Share Buybacks | $1.0M | $1.0M | - | - | - |